↓ Skip to main content
GLASS Consortium

Publications

Papers are listed from PubMed IDs and DOIs. Title, authors, journal, and links are fetched from PubMed and Crossref when the site is built.

2026

  1. Divergent genomic evolution in astrocytomas and oligodendrogliomas

    Chowdhury T, Tesileanu CMS, Kocakavuk E, Johnson KC, Lee JH, Erson-Omay Z, …, Varn FS, Verhaak RGW

    Nature 2026

    DOIPubMed
  2. Acquired genetic and cell-state changes in IDH-mutant glioma progression

    Johnson KC, Spitzer A, Varn FS, Nomura M, Garofano L, Chowdhury T, …, Tirosh I, Verhaak RGW

    Nature 2026;655(8124):1048-1059

    DOIPubMedFree full text

2025

  1. Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling

    Vallentgoed WR, Hoogstrate Y, van Garderen KA, van Hijfte L, van Dijk E, Kouwenhoven MCM, …, Wesseling P, French PJ

    Nat Cancer 2025;6(10):1693-1713

    DOIPubMed
  2. Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics

    Spitzer A, Johnson KC, Nomura M, Garofano L, Nehar-Belaid D, Darnell NG, …, Tirosh I, Suvà ML

    Nat Genet 2025;57(5):1168-1178

    DOIPubMedFree full text
  3. The multilayered transcriptional architecture of glioblastoma ecosystems

    Nomura M, Spitzer A, Johnson KC, Garofano L, Nehar-Belaid D, Galili Darnell N, …, Suvà ML, Tirosh I

    Nat Genet 2025;57(5):1155-1167

    DOIPubMedFree full text
  4. Programs, origins and immunomodulatory functions of myeloid cells in glioma

    Miller TE, El Farran CA, Couturier CP, Chen Z, D'Antonio JP, Verga J, …, Shalek AK, Bernstein BE

    Nature 2025;640(8060):1072-1082

    DOIPubMedFree full text

2024

  1. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

    Malta TM, Sabedot TS, Morosini NS, Datta I, Garofano L, Vallentgoed W, …, Iavarone A, Noushmehr H

    Cancer Res 2024;84(5):741-756

    DOIPubMedFree full text

2023

  1. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting

    Rautajoki KJ, Jaatinen S, Hartewig A, Tiihonen AM, Annala M, Salonen I, …, Haapasalo H, Nykter M

    Acta Neuropathol Commun 2023;11(1):176

    DOIPubMedFree full text
  2. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells

    Fabro F, Kers TV, Feller KJ, Beerens C, Ntafoulis I, Idbaih A, …, Lamfers MLM, Leenstra S

    Int J Mol Sci 2023;24(21)

    DOIPubMedFree full text
  3. Identifying predictors of glioma evolution from longitudinal sequencing

    Mu Q, Chai R, Pang B, Yang Y, Liu H, Zhao Z, …, Jiang T, Wang J

    Sci Transl Med 2023;15(716):eadh4181

    DOIPubMed
  4. Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

    Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, Noushmehr H, Verhaak RGW

    Neuro Oncol 2023;25(9):1721-1723

    DOIPubMedFree full text
  5. Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling

    Jeon HM, Kim JY, Cho HJ, Lee WJ, Nguyen D, Kim SS, …, Nam DH, Lee J

    Cancer Cell 2023;41(8):1480-1497.e9

    DOIPubMedFree full text
  6. Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence

    Andrieux G, Das T, Griffin M, Straehle J, Paine SML, Beck J, …, Rahman R, Chakraborty S

    Genome Med 2023;15(1):48

    DOIPubMedFree full text
  7. Molecular and clinical characterization of PTRF in glioma via 1,022 samples

    Sun S, Yang C, Wang K, Huang R, Zhang KN, Liu Y, …, Zhao Z, Jiang T

    BMC Cancer 2023;23(1):551

    DOIPubMedFree full text
  8. Transcriptome analysis reveals tumor microenvironment changes in glioblastoma

    Hoogstrate Y, Draaisma K, Ghisai SA, van Hijfte L, Barin N, de Heer I, …, Robe PA, French PJ

    Cancer Cell 2023;41(4):678-692.e7

    DOIPubMed
  9. Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors

    Kashani E, Schnidrig D, Gheinani AH, Ninck MS, Zens P, Maragkou T, …, Ng CKY, Vassella E

    Neuro Oncol 2023;25(4):662-673

    DOIPubMedFree full text

2022

  1. Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma

    Wu L, Wu W, Zhang J, Zhao Z, Li L, Zhu M, …, Jiang T, Wang Q

    Cancer Discov 2022;12(12):2820-2837

    DOIPubMedFree full text
  2. Glioma progression is shaped by genetic evolution and microenvironment interactions

    Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, …, Verhaak RGW, GLASS Consortium

    Cell 2022;185(12):2184-2199.e16

    DOIPubMedFree full text
  3. Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas

    Liu Y, Sathe AA, Abdullah KG, McBrayer SK, Adams SH, Brenner AJ, …, Walker JM, Richardson TE

    Acta Neuropathol Commun 2022;10(1):32

    DOIPubMedFree full text
  4. Environmental and sex-specific molecular signatures of glioma causation

    Claus EB, Cannataro VL, Gaffney SG, Townsend JP

    Neuro Oncol 2022;24(1):29-36

    DOIPubMedFree full text

2021

  1. Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes

    Wu F, Liu YW, Li GZ, Zhai Y, Feng YM, Ma WP, Zhao Z, Zhang W

    Br J Cancer 2021;125(2):255-264

    DOIPubMedFree full text
  2. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer

    Kocakavuk E, Anderson KJ, Varn FS, Johnson KC, Amin SB, Sulman EP, …, Barthel FP, Verhaak RGW

    Nat Genet 2021;53(7):1088-1096

    DOIPubMedFree full text
  3. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma

    Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, …, Horbinski C, Stegh AH

    Sci Transl Med 2021;13(584)

    DOIPubMedFree full text
  4. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities

    Garofano L, Migliozzi S, Oh YT, D'Angelo F, Najac RD, Ko A, …, Lasorella A, Iavarone A

    Nat Cancer 2021;2(2):141-156

    DOIPubMedFree full text
  5. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

    Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, …, Bigner DD, Ashley DM

    Nat Commun 2021;12(1):352

    DOIPubMedFree full text

2020

  1. iGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium

    Bakas S, Ormond DR, Alfaro-Munoz KD, Smits M, Cooper LAD, Verhaak R, Poisson LM

    Neuro Oncol 2020;22(10):1545-1546

    DOIPubMedFree full text
  2. The Magnifying GLASS: Longitudinal Analysis of Adult Diffuse Gliomas

    Narayanan A, Turcan S

    Cell 2020;180(3):407-409

    DOIPubMed

2019

  1. Longitudinal molecular trajectories of diffuse glioma in adults

    Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, …, Verhaak RGW, GLASS Consortium

    Nature 2019;576(7785):112-120

    DOIPubMedFree full text

2018

  1. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium

    GLASS Consortium

    Neuro Oncol 2018;20(7):873-884

    DOIPubMedFree full text